STOCK TITAN

Mirati Therapeutics, Inc. - $MRTX STOCK NEWS

Welcome to our dedicated page for Mirati Therapeutics news (Ticker: $MRTX), a resource for investors and traders seeking the latest updates and insights on Mirati Therapeutics stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Mirati Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Mirati Therapeutics's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.3%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.72%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.28%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.95%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.53%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.68%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.71%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.51%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.82%
Tags
Mirati Therapeutics, Inc.

Nasdaq:MRTX

MRTX Rankings

MRTX Stock Data

4.12B
38.91M
1.72%
117.76%
6.26%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
San Diego

About MRTX

mirati therapeutics develops molecularly targeted, single agent and immuno-oncology combination therapies intended to treat cancer. mirati's approach combines the three most important factors in oncology drug development, 1) researching and developing drug candidates that target genetic and epigenetic drivers of cancer, 2) designing creative and agile clinical development strategies that select for patients whose tumors are dependent on specific driver alterations, and 3) leveraging a highly accomplished oncology precision medicine leadership team. the mirati team uses a blueprint – proven by their prior work – for developing potential breakthrough cancer therapies, with accelerated development paths, in order to improve outcomes for patients. mirati is advancing three drug candidates through clinical development for multiple oncology indications.